Loading
Latest filing published 19 Aug 2026 for Zentalis Pharmaceuticals, Inc., €13.1M.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Walters Group in Zentalis Pharmaceuticals, Inc. We count 2 filings; the first trade dates from 31 December 2025 and the latest from 14 August 2026.
No open-market sale appears; the market trades are 2 purchases worth €19.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 2 purchases and no sales.
The latest filing, published on 19 August 2026, reports an open-market purchase of €13.1M in Zentalis Pharmaceuticals, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations